linjc16/ctgov huggingface dataset:
Prevalence of MLFA Types and MD in Egyptian Children With Erupted Canines

Study Overview
=================
Brief Summary
-----------------
Descriptive observational cross sectional study Outpatient at faculty of dentistry Cairo university pediatric dentistry department clinic with midline diastema and fully erupted canines will be examined and assess type of frenal attachment to see if correlation present or not

Official Title
-----------------
Prevalence of Maxillary Labial Frenal Attachments Types and Midline Diastema in Egyptian Children With Fully Erupted Maxillary Permanent Canines

Conditions
-----------------
Destructive Attachment of Labial Frenum

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Systemically healthy children Egyptian children with fully erupted canines Patient presented for routine evaluation or treatment Exclusion Criteria: Children who exhibited congenital anomalies or orofacial defects Children with previous trauma in frenal area which affect its morphology Children have previous surgical intervention in labial frenum or in the maxillary anterior region. Children have any syndromes or habits that affect the anterior maxillary region.

Ages Eligible for Study
-----------------
Minimum Age: 9 Years
Maximum Age: 13 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Incidence of Midline diastema | measuring diastema in millimeters using calibrated ruler | 1 year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Frenal attachment types | Direct visual method | 1 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Midline diastema, Prevalence, Maxillary frenal types
Omega3 PUFA in Head Trauam

Study Overview
=================
Brief Summary
-----------------
Traumatic brain injury (TBI) is major health problem that stands as a significant cause of death and permanent disability. TBI is considered as global public health epidemic. On pathophysiologic basis, TBI is described as occurring in two phases, primary and secondary. Once a primary insult occurs like trauma or ischemia, the secondary injury begins though main four mechanisms; ischemia, brain edema, axonal injury and neuro-inflammation. Omega-3 PUFAs (Polyunsaturated fatty acids) are postulated to have neuroregenerative properties with the ability to impact all four main mechanisms of the secondary injury Patients will be allocated into one of two groups through a random table generation; Control group in which patients will follow our local protocol for TBI management without SMOF-lipid infusion. SMOF-lipid group in which patients will receive 0.5 g/Kg SMOF lipid 10% emulsion (Lipid emulsion for intravenous nutrition containing; 6% soybean oil / 6% medium chain triglycerides / 5% olive oil / 3%fish oil) daily over 12 hours starting once admitted to ICU for 7 days

Conditions
-----------------
Traumatic Brain Injury

Intervention / Treatment
-----------------
* Drug: omega-3 enriched SMOF lipid emusion


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: mild to moderate head trauma Exclusion Criteria: sensitivity to SMOF lipid severe head trauama

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| No Intervention: Control group<br>Control group in which patients will follow our local protocol for TBI management without SMOF-lipid infusion | |
| Experimental: SMOF group<br>SMOF-lipid group in which patients will receive 0.5 g/Kg SMOF lipid 10% emulsion (Lipid emulsion for intravenous nutrition containing; 6% soybean oil / 6% medium chain triglycerides / 5% olive oil / 3%fish oil) daily over 12 hours starting once admitted to ICU for 7 days. | Drug: omega-3 enriched SMOF lipid emusion<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Glasgow coma scale after 48 hour of infusion |  | 48 hours |
Early Multimodal Neuromonitoring For Spontaneous Intracerebral Hemorrhage (ICH)

Study Overview
=================
Brief Summary
-----------------
The investigators intend to assess the predictive value of early (first 48 hours) multimodal neuromonitoring parameters concerning late survival in critically ill intracerebral hemorrhage (ICH) patients.

Detailed Description
-----------------
Retrospective observational study based on analyzing the first 48 hours of the multimodal neuromonitoring signal, from spontaneous ICH patients, whose treatment includes invasive intraparenchymal neuromonitoring, treated from January 2015 to September 2021 in a tertiary hospital.

Official Title
-----------------
Early Multimodal Neuromonitoring Parameters as Prognostic Factors For Critically Ill Spontaneous ICH Patients

Conditions
-----------------
Intracerebral Hemorrhage, Critically Ill, Intracranial Pressure, Cerebral Perfusion Pressure, Prognostic

Intervention / Treatment
-----------------
* Diagnostic Test: Multimodal Neuromonitoring


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Spontaneous Intracerebral Hemorrhage ICU admission Need of Sedation and Ventilatory Support Need of Intracerebral Neuromonitoring Exclusion Criteria: Etiology for Intracerebral hemorrhage such as tumor, vascular malformation, ischemic transformation.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Diagnostic Test: Multimodal Neuromonitoring|Invasive Multimodal Neuromonitoring|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Survival | 1 and 6 months survival | 1 and 6 months | 
| Functional Outcome | 6 month functional outcome with Modified Rankin Scale - 0 (No symptoms); 1 (No significant disability); 2 (Slight disability); 3 (Moderate disability); 4 (Moderately Severe Disability); 5 (Severe Disability); 6 (Dead). | 6 month |
Study on the Safety and Effects on Lipids of FM-VP4 in Subjects With Primary Hypercholesterolemia

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to evaluate the safety and effects on lipids of FM-VP4 administered for 12 weeks in subjects with mild to moderate primary hypercholesterolemia.

Official Title
-----------------
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of the Safety and Effects on Lipids of 12 Weeks of 2 Doses of FM-VP4 in Subjects With Primary Hypercholesterolemia

Conditions
-----------------
Hypercholesterolemia

Intervention / Treatment
-----------------
* Drug: Disodium Ascorbyl Phytostanol Phosphate (FM-VP4)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Mild to moderate primary hypercholesterolemia Able to give informed consent and to comply with study procedures (including diet) Exclusion Criteria: Homozygous familial hypercholesterolemia Age <18 or >75 years Pregnant women or women of child-bearing potential

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Disodium Ascorbyl Phytostanol Phosphate (FM-VP4)|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Percent change from baseline in LDL-C at 12 weeks |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Percent change from baseline in TC, HDL-C, TG, HDL:LDL ratio and CRP at 12 weeks |  |  | 
| Percent change from baseline in serum lipids at 2, 4 and 8 weeks |  |  | 
| Safety |  |  |
Impact of Tight Glycaemic Control in Acute Myocardial Infarction

Study Overview
=================
Brief Summary
-----------------
To determine whether tight glycaemic control with insulin improves myocardial function and myocardial perfusion (measured by myocardial contrast echocardiography) and novel vascular risk factors in patients with acute myocardial infarction and hyperglycaemia.

Detailed Description
-----------------
We will randomise patients with acute myocardial infarction and blood glucose levels (BGLs) >=10mmol/L within 24 hours of pain onset, to either tight glucose control (aiming BGLs 4.5 - 7mmol/L) with an insulin infusion (for 24 hours) followed by subcutaneous insulin or standard control (BGL 6 - 12mmol/L) without the use of an insulin infusion. Serial myocardial contrast echocardiography will measure changes in myocardial perfusion and function from baseline to 3 months between each group. We will also measure changes in inflammatory and endothelial markers over this time to see whether tight glucose control improves these surrogate endpoints.

Official Title
-----------------
Impact of Tight Glycaemic Control With Insulin on Novel Vascular Disease Risk Factors and Myocardial Function and Perfusion in Acute Myocardial Infarction Patients With Hyperglycaemia

Conditions
-----------------
Myocardial Infarct, Hyperglycemia

Intervention / Treatment
-----------------
* Drug: Insulin (tight blood glucose control)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age >=18years Acute Myocardial Infarction Blood Glucose Level >=10mmol/L Wall motion abnormality on baseline echocardiogram Exclusion Criteria: Active infection/inflammation Cardiac shunt Cognitive Impairment Insulin allergy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Insulin (tight blood glucose control)|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Difference in the change in wall motion score index between admission, day 3-5 and after 3 months in the two treatment arms. |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Changes in inflammatory/endothelial markers and myocardial perfusion from admission, day 3-5 and after 3 months between the two treatment arms |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Acute Myocardial Infarction, Hyperglycaemia, Insulin Infusion
Memory and Attention Disorders and Malnutrition in Hospital Setting

Study Overview
=================
Brief Summary
-----------------
This is a cross-sectional observational study that investigates the prevalence of memory disorders, attention disorders (suggesting delirium), and malnutrition in hospitalized older adults (aged 70 years or over) in a tertiary care centre, using rapid screening toos (Six-item screener for memory disorders, Months of the Year Backwards Test for delirium, and NRS-2002 and Mini Nutritional Assessment Short Form for malnutrition).

Official Title
-----------------
Prevalence of Memory and Attention Disorders and Malnutrition in Hospitalized Older Adults (Muistitoimintojen ja Tarkkaavaisuuden häiriöiden ja Vajaaravitsemuksen Yleisyys iäkkäillä Sairaalahoidossa Olevilla Potilailla [Finnish])

Conditions
-----------------
Dementia, Delirium, Cognitive Impairment, Malnutrition

Intervention / Treatment
-----------------
* Diagnostic Test: Screening for memory disorders, attention disorders, and malnutrition


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Hospitalized in Tampere University Hospital (excl. psyciatry, pediatrics, ICU) Able to communicate in Finnish Exclusion Criteria: Unable to communicate because of unconciuousness, critical health status, or communication difficulties Having a (surgical) procedure at the time of data collection

Ages Eligible for Study
-----------------
Minimum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Patients aged 70 or over<br>Patients eligible for the study will undergo screening for memory disorders, attention disorders, and malnutrition | Diagnostic Test: Screening for memory disorders, attention disorders, and malnutrition<br>* Screening for memory disorders, attention disorders, and malnutrition, using Six-Item Screener, Months of the Year Backwards Test, and NRS-2002 and MNA-SF, respectively.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Prevalence of memory disorders | Abnormal result in Six-Item Screener | day of recruitment | 
| Prevalence of attention disorders | Abnormal result in Months of the Year Backwards Test | day of recruitment | 
| Prevalence of malnutrition and risk of malnutrition | Abnormal result based on nutritional status screening tools | day of recruitment |
Smoking in the Paris Fire Brigade and Comparison According to the Type of Service (Permanent or On-call)

Study Overview
=================
Brief Summary
-----------------
Tobacco use is one of the world's leading preventable causes of disease and premature death, and the physician has a central role in detecting smokers and helping them to quit. Tobacco use in the military undermines fitness, readiness and performance, and increases health care costs. A study conducted on a French Army contingent on external operations in Afghanistan have shown an increase in tobacco use in situation of operational constraints (stress, shift work, etc.). However, another study conducted in Ivory Coast on a mobile gendarmerie squadron showed no significant difference. Among the American firefighters who have been exposed to the 9/11 World Trade Center attacks, smoking have been shown to play an aggravating role in the recovery of lung function. This study is aimed at assessing smoking prevalence in the Paris Fire Brigade, which is composed of young and healthy sportsmen and women who are exposed to strong operational constraints.

Official Title
-----------------
Smoking in the Paris Fire Brigade and Comparison According to the Type of Service (Permanent or On-call)

Conditions
-----------------
Tobacco Use

Intervention / Treatment
-----------------
* Other: Questionnaire


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: To be 18 years of age or older To be French To be an active military member To work in the Paris Fire Brigade Exclusion Criteria: To be a civilian To be a reservist To be a foreigner

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: Questionnaire|The participants will have to filled out a questionnaire about their working conditions and their lifestyle habits.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Proportion of smokers | The smoking status (smoker or non-smoker) will be determined according to the responses to the questionnaire. The proportion of smokers will be calculated by dividing the number of smokers by the total number of participants. | At enrollment (day 1) |
Evaluating the Effect of Mucinex 1200mg on Mucociliary and Cough Clearance During an Acute Respiratory Infection

Study Overview
=================
Brief Summary
-----------------
The purpose of this research study is to explore the mechanism of action of Mucinex, an oral, over-the-counter, FDA approved expectorant in patients with acute respiratory tract infections.

Conditions
-----------------
Acute Respiratory Infection

Intervention / Treatment
-----------------
* Drug: Mucinex
* Drug: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Symptoms of cough, thickened mucus and chest congestion Able to produce sputum Non Smoker Exclusion Criteria: Pregnant Smokers Fever above 101°F Any chronic illness

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Guaifenesin<br>Mucinex 1200mg (Guaifenesin)given as 2, 600mg tablets | Drug: Mucinex<br>* Mucinex 1200mg (Guaifenesin) given as 2,600mg tablets, one time on day 1 of the study<br>|
| Placebo Comparator: Placebo<br>Given as 2 tablets | Drug: Placebo<br>* Placebo given as 2 tablets<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Percent of Inhaled Radioactive Tracer Particles Cleared From Lungs | Percentage of inhaled radioactive tracer (Ave180Clear) | 3 hours following inhalation of radioactive tracer particles | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Guaifenesin AUC(0-3) |  | 3 hours following dose administration | 
| Assess Sputum Properties (Objective Measures) and Symptoms (Subjective Measures) After Treatment With Mucinex or Placebo. |  | Within 10 days of developing symptoms associated with a respiratory tract infection | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Acute Respiratory Infection, Mucociliary, Cough Clearance, Guaifenesin
Open-label Trial of Imatinib Mesylate in Patients With Unresectable Recurrent Glioblastoma Multiforme Expressing PDGFR (Platelet Derived Growth Factor Receptors)

Study Overview
=================
Brief Summary
-----------------
This is an open label clinical trial of imatinib mesylate 800 mg po/day in a population of patients with unresectable, recurrent glioblastoma multiforme. Patients will be treated for up to 12 months

Official Title
-----------------
Open-label Trial of Imatinib Mesylate in Patients With Unresectable Recurrent Glioblastoma Multiforme Expressing PDGFR (Platelet Derived Growth Factor Receptors)

Conditions
-----------------
Glioblastoma

Intervention / Treatment
-----------------
* Drug: imatinib mesylate


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Histologically documented diagnosis of GBM. Immunohistochemical documentation of expression of PDGFR. Unresectable, recurrent disease by MRI and spectroscopy Exclusion Criteria: Treatment with any other investigational agents within 28 days of first day of study drug dosing. Concurrent chemotherapy. Concurrent radiotherapy. Other protocol-defined exclusion criteria may apply.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: imatinib mesylate|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| PFS (progression free-survival), defined by the percentage of patients without evidence of progressive disease in 6 months |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Objective Tumoral Response defined by RECISt criteria performed by MRI |  |  | 
| OS (overall survival) |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Glioblastoma, Brain tumors, Imatinib, PDGFR
Comparison of Insulin Detemir Versus Insulin NPH on Weight Change in Overweight and Obese With Type 2 Diabetes

Study Overview
=================
Brief Summary
-----------------
This trial is conducted in Europe. The purpose of the trial is to investigate the effect of insulin detemir on weight change in overweight and obese patients with type 2 diabetes.

Official Title
-----------------
Comparison of the Effect of Insulin Detemir Versus Insulin NPH Both With Insulin Aspart on Weight Change in Overweight and Obese Subjects With Type 2 Diabetes

Conditions
-----------------
Diabetes, Diabetes Mellitus, Type 2

Intervention / Treatment
-----------------
* Drug: insulin detemir
* Drug: insulin NPH
* Drug: insulin aspart


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: HbA1c: 7.5-11.0% BMI: 25-40 kg/m2 Exclusion Criteria: Treatment with any OAD (Oral Antidiabetic Drugs) except metformin

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: insulin detemir|nan|
|Drug: insulin NPH|nan|
|Drug: insulin aspart|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Body weight loss |  | after 26 weeks of treatment | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| HbA1c |  |  | 
| Incidence of hypoglycaemia |  |  |